Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The patient took the second dose of Vivotif 19 days after first dose; Case reference number US-BN-2025-001132 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-1576) on 30-Jun-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 10-Jun-2025, the patient took first doses of Vivotif (batch number: unknown) at unknown dose, route or site of administration for unknown indication. On 29-Jun-2025, 19 days after first dose, the patient took second dose of Vivotif (batch number: unknown) at unknown dose, route or site of administration (explicitly coded as 'inappropriate schedule of product administered'). At the time of the initial report, it was unknown if patient experienced any adverse events due to Vivotif. No further information provided.; Reporter's Comments: A male patient of unspecified age took the second dose of Vivotif on the day 19 after the first dose, which is considered as inappropriate schedule of product administered. It was unknown if patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age took the second dose of Vivotif on the day 19 after the first dose, which is considered as inappropriate schedule of product administered. It was unknown if patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.